PET/CT Report for Stomach Cancer Evaluation
Uploaded by
saurabh pathakPET/CT Report for Stomach Cancer Evaluation
Uploaded by
saurabh pathakCommon questions
Powered by AIThe evaluations noted normal physiological tracer distribution in the brain, with no abnormalities in the head and neck or thorax, suggesting no signs of metastasis in these regions. Contrarily, the abdomen and pelvis revealed non-FDG avid pathologies like mild wall thickening and lymph nodes, indicating some anatomical changes yet no active metabolic abnormalities. This juxtaposition highlights a scenario where structural abnormalities exist without corresponding metabolic activity, warranting further clinical correlation for comprehensive assessment .
The PET/CT study of the patient's abdomen and pelvis revealed normal liver parenchyma and enhancement pattern with no focal lesions or abnormal increased FDG uptake. It noted non-FDG avid low volume asymmetric wall thickening in the distal body and pylorus of the stomach, which was predominantly along the lesser curvature. This thickening was approximately 0.9 cm, causing mild luminal narrowing and distension of the stomach with some mild perigastric fat stranding. Additionally, non-FDG avid subcentimetric gastrohepatic and portocaval lymph nodes, omental haziness, nodularity, and mild right hydrocele were observed ."
The serum creatinine and blood glucose values are relevant for assessing the patient's baseline health status and potential risk factors during the PET/CT scan. Serum creatinine of 0.9 mg/dL suggests normal kidney function, which is important for the safe administration of contrast during CT imaging. Blood glucose at 124 mg/dL is slightly above normal fasting range, which needs to be considered when evaluating FDG uptake, as glucose levels can influence the distribution and uptake of the radiotracer .
The document recommends using MRI to further evaluate potential brain metastases if there is a strong suspicion, as small lesions may not be detected by an FDG PET/CT study due to normal high physiological uptake in the brain .
CT images for attenuation correction are crucial in a PET/CT scan as they help correct the PET images for any distortions caused by varying tissue densities. This process enables more precise localization of tracer uptake and improved image quality, ensuring accurate visualization and differentiation of metabolic activity, essential in oncological imaging for precise diagnosis and treatment planning .
'Non-FDG avid' indicates that a lesion does not show increased uptake of the fluorodeoxyglucose (FDG) radiotracer, suggesting it is metabolically inactive. This can imply that the lesion might not be actively growing or is not currently exhibiting hypermetabolic activity typically associated with malignant tissues .
The report advises bringing previous reports and PET/CT CDs for follow-up scans to enable comparison with past studies, ensuring accurate monitoring of disease progression or regression. This continuity helps in detecting any new changes that may require intervention and assessing response to treatment, given the patient's ongoing cancer care .
Clinical correlation is recommended because imaging findings alone may not reflect the complete clinical picture of the patient's health status. Factors such as symptoms, physical examination findings, laboratory results, and the patient's overall clinical context should be considered to make an informed decision on further management or treatment adjustments, especially given the patient's cancer history and current treatment status .
The PET/CT scan findings showed no significant changes compared to the previous study conducted on March 26, 2025. The scan continued to show metabolically inactive mild wall thickening of the stomach's distal body and pylorus, with unchanged omental haziness and nodularity. No new abnormal hypermetabolic foci were noted in the rest of the visualized body .
Fluorodeoxyglucose (FDG) is a radiotracer used in PET/CT scans because it mimics glucose uptake in the body, with higher uptake in metabolically active tissues. This property allows for the visualization and assessment of hypermetabolic activity, crucial in identifying cancerous lesions and monitoring treatment efficacy, as cancer cells often exhibit increased glucose metabolism compared to normal cells .